

19 **Abstract**

20 **Background:**

21 Autoantibodies to the *N*-methyl-D-aspartate receptor (NMDAR-Abs) in autoimmune
22 encephalitis have been associated with prominent psychiatric symptoms. The aims of the
23 present study are to identify the prevalence of NMDAR-Abs in adolescents with early onset
24 psychosis disorders (EOP) and healthy controls (HC) and examine its clinical significance.

25 **Method:**

26 Plasma samples were acquired from 46 adolescent EOP patients and 69 age- and sex matched
27 HC, and assessed for the presence of immunoglobulin G NMDAR-Abs. All participants
28 underwent psychiatric evaluation, neurological examination and head magnetic resonance
29 imaging.

30 **Results:**

31 NMDAR-Abs were detected in three of 46 (6.5%) EOP patients and in two of 69 (2.9%) HC.
32 One NMDAR-Abs EOP patient presented with unusual psychopathology and minor T1
33 weighted lesions of vasculopathological origin located bi-frontally and in the basal ganglia,
34 and had a recent diagnosis of a separate autoimmune disease. One NMDAR-Abs HC
35 displayed a T2 weighted FLAIR hyperintensity lesion in the left frontal lobe. The remaining
36 three NMDAR-Abs participants were two EOP patients without neurological or radiological
37 findings, and one HC without any clinical findings.

38 **Conclusions:**

39 We report the presence of NMDAR-Abs in both adolescent EOP patients and HC, similar to
40 the incidence in other studies. This may support the hypothesis of an immunological disease
41 component in a small proportion of adolescent psychosis, but the positive antibody tests must
42 be carefully interpreted and reviewed within the individual clinical context.

43

44 **Introduction**

45 Psychosis, as observed in severe mental illness, is a condition with unknown
46 pathophysiology. The dopamine hypothesis only partially explains the symptoms occurring in
47 affected individuals [1, 2], but pharmacological studies in both humans and animals indicate
48 that hypoactivation of *N*-methyl-D-aspartate receptors (NMDAR) may cause the presynaptic
49 hyperdopaminergia related to schizophrenia [3, 4]. Dysfunction in the glutamatergic system in
50 patients with schizophrenia has been supported by positron-emission tomography (PET) and
51 single-photon emission computed tomography (SPECT) studies, showing elevated levels of
52 glutamate in the medial prefrontal cortex and the basal ganglia [5]. Within psychiatric
53 research, the likelihood that a specific immune-mediated mechanism may define a biological
54 subgroup of patients has gained considerable attention.

55 Anti-NMDA receptor encephalitis (ANRE) is an autoimmune neurological condition
56 associated with IgG antibodies directed towards the NMDA receptor (NMDAR-Abs), which
57 leads to NMDAR hypofunction [6]. There is sometimes a non-specific prodromal phase
58 (viral-like illness) leading into psychiatric symptoms, most commonly delusions, auditory and
59 visual hallucinations, mania, agitation, aggression, and unusual and bizarre behaviors [7].
60 Cognitive deficits and seizures with movement disorders can be observed within the first few
61 weeks, with the possibility of hypoventilation and autonomic instability variably following
62 [7]. Thus, ANRE has demonstrated further that loss of glutamatergic signaling can cause
63 psychotic symptoms. Patients with ANRE are often seen initially by psychiatrists because of
64 their psychiatric presentations [8] and indeed there are reports of ANRE patients with solely
65 psychiatric symptoms, both in adult and in pediatric patients [9]. As a result, there have been
66 many studies examining the prevalence of antibodies in adult psychiatric patients compared to
67 healthy controls [10].

68 Early onset psychosis disorder (EOP) is defined as affective and non-affective psychotic
69 disorders with disease onset before the age of 18 years [11]. EOP is a rare occurring condition
70 with an estimated prevalence ranging from 0.05% to 0.5%, increasing during adolescence [12,
71 13]. EOP constitutes a group of severely debilitating conditions, including schizophrenia
72 which is one of the main causes of disease burden in adolescents [14]. Within the EOP group,
73 compared with adult onset patients, there are patients with poorer long term outcome [15],
74 longer durations of untreated psychosis and a greater number of coexisting conditions [16].
75 To our knowledge, only one study on 43 pediatric EOP patients and 43 pediatric healthy
76 controls assessed the presence of NMDAR-Abs and found an incidence of 5/43 (11.6%) in
77 EOP without positives in the controls [17]. They found no clinical differences between
78 antibody-positive and antibody-negative patients.

79 The study aim was to examine the prevalence of plasma IgG NMDAR-Abs in adolescent EOP
80 patients and HC and to assess its association with age, sex, diagnosis and psychiatric features.

81

82 **Materials and Methods**

83 *Participants*

84 We examined the presence of NMDAR-Abs in 115 adolescents in this Scandinavian multi-
85 center study with EOP (n = 46) and HC (n = 69). The study sample consisted of two clinical
86 cohorts - one from the University of Oslo, Oslo, Norway and one from the Karolinska
87 Institute, Stockholm, Sweden. Written informed consent was obtained from all participants
88 and from parents/next-of-kin. The study was conducted in accordance with the Helsinki
89 Declaration and approved by both the Swedish and the Norwegian National Committee for
90 Ethics in Medical Research.

91 The Swedish sample consisted of 25 EOP patients and 34 HC participating in the Stockholm
92 Child and Adolescent Psychosis Study (SCAPS). Patients aged 12-18 years of both sexes
93 were recruited from the specialist care unit of psychosis and bipolar disorder in the
94 department of Child and Adolescent Psychiatry at Sachs Children's hospital in Stockholm,
95 Sweden, and assessed by child- and adolescent psychiatry specialists working in the clinic.
96 HC living in the Stockholm area were recruited using a population registry to ensure a similar
97 demographic, age and sex distribution for the controls. The Norwegian sample consisted of 21
98 EOP patients and 35 HC participating in the Thematically Organized Psychosis research study
99 for Youth (Youth-TOP), part of the Norwegian Centre for Mental Disorders Research
100 (NORMENT). Patients aged 12-18 years of both sexes were recruited from the adolescent
101 psychiatric inpatient units and outpatient clinics in the Oslo region and assessed by
102 researchers consisting of trained psychiatrists and psychologists. HC, living in the Oslo area,
103 were recruited from the Norwegian population registry, ensuring that the controls were
104 similar to the included patients with regards to age and sex distribution and socio-
105 demographic area. HC, for both samples, were excluded if they had been in contact with child

106 and adolescent mental health care units, or if they currently met the criteria of a psychiatric
107 disorder.

108 For both samples, inclusion criteria were (1) early onset psychosis according to DSM-IV
109 (Diagnostic and Statistical Manual of Mental Disorders, 4th edition), including schizophrenia
110 spectrum disorders (schizophrenia, schizophreniform disorder, schizoaffective disorder),
111 affective psychotic disorder (bipolar I disorder and major depressive disorder with psychotic
112 features), and other psychotic disorders (psychotic disorder not otherwise specified (NOS),
113 delusional disorder and brief psychotic disorder), (2) age between 12 and 18 years, (3)
114 language abilities to complete interviews and self-rating tests and (4) written informed
115 consent. General exclusion criteria were IQ < 70, previous moderate/severe head injury, a
116 diagnosis of substance-induced psychotic disorder and organic brain disease.

117 *Diagnostic and Clinical Assessment with Regards to Psychiatric Diagnoses*

118 The Swedish patients were assessed and diagnosed in accordance with ICD-10 [18] by their
119 managing child and adolescent psychiatrists during their contact with the psychiatric unit. The
120 Norwegian patients were diagnosed in accordance with the DSM-IV criteria using the
121 Norwegian version of the Schedule for Affective Disorders and Schizophrenia for School
122 Aged Children (6-18 years): Present and Lifetime Version (Kiddie-SADS) [19] and the
123 Positive and Negative Syndrome Scale (PANSS) [20] for the assessment of current symptoms
124 of psychosis. Functional outcome was assessed using the Children's Global Assessment Scale
125 (CGAS)[21], which is a measure of social, psychological and occupational functioning in
126 both samples. Assessment included a general physical examination including a neurological
127 examination consisting of the evaluation of gait, coordination, motor movements, reflexes and
128 sensory examination. Data from the neurological examination was incomplete in the Swedish
129 sample.

130 *Clinical Characterization and ANRE*

131 Upon determining whether antibody positive participants had symptoms coinciding with
132 ANRE; therefore, of particular interest in this study, we read through participants' diagnostic
133 and clinical assessments. These assessments were based on information from the participant,
134 their parents and managing clinicians and from their medical records. Our goal was to identify
135 possible symptoms and findings associated commonly with ANRE [8].

136 *Medication*

137 Information regarding use of psychotropic medication in the Swedish sample was retrieved
138 from the physicians treating the patients. For the Norwegian sample current and lifetime use
139 of medication was collected from patients and/or their closest relatives using a structured
140 questionnaire in an interview conducted by a research psychiatrist or psychologist. In some
141 instances, information was retrieved from the physicians/psychologists treating the patients.

142 *NMDA Receptor Antibody (NMDAR-Abs) Measurements*

143 Blood sampling was conducted at baseline for all participants. The plasma samples, which
144 had been in a storage facility at -20 C, were sent to the Department of Clinical Neurosciences
145 at the John Radcliffe Hospital in Oxford, England in 2015 for analysis of NMDAR-Abs.

146 NMDAR-Abs were measured (blind to the EOP or HC status of the sample) by indirect cell
147 surface immunocytochemistry of transfected cells as used for routine diagnostic assays by the
148 Oxford Neuroimmunology service since 2008. Briefly, live HEK293 cells are transfected with
149 cDNAs of NR1 and NR2B subunits and incubated in human serum (1:20 initial dilution) or
150 CSF (1:1 initial dilution) before fixation, followed by Alexa-Fluor labelled antihuman IgG.
151 Antibodies binding to the cell surface of the live NMDAR-HEK293 cells were identified by
152 fluorescence microscopy. A visual scoring system (0–4) is used and positive samples were

153 repeated in a separate assay where they are also checked for specificity by lack of binding to
154 HEK293 cells expressing an alternative antigen. As with other assays, scores of 0 are reported
155 as negative and scores of 2–4 are reported as positive. Scores of 1 were initially reported as
156 Low Positive, but after 2011 only scores of 1.5 are reported as Low Positive.

157 *MRI Acquisition and Assessment*

158 Swedish participants underwent MRI scans on a 3 Tesla Discovery 750 scanner (GE Medical
159 Systems) at the MR Research Centre at the Karolinska Institute in Stockholm. Norwegian
160 participants were scanned using a 3 Tesla Signa HDxt scanner (GE Medical Systems) at the
161 Department of Neuroradiology, Oslo University Hospital. A neuro-radiologist evaluated MRI
162 images for pathological changes, including white matter hyper-intensity lesions. For both
163 scanners, the assessment was based on structural MRI T1 weighted and T2-weighted fluid-
164 attenuated inversion recovery (FLAIR) sequences.

165

166 **Results**

167 Five of the 115 samples had detectable NMDAR-Abs, of which three of 46 (6.5%) were EOP
168 patients and two of 69 (2.9%) were healthy participants.

169 Demographics and clinical features of antibody positive and antibody negative patients are
170 shown in Table 1. The mean age of patients in the antibody positive and antibody negative
171 groups was 14.5 ± 2.3 and 16.5 ± 1.8 years, respectively, with a significant difference being
172 observed between groups ($p = 0.026$). There was a higher proportion of females in the study
173 overall, with ratios of 72.1% and 66.7% in antibody-negative and antibody-positive groups,
174 respectively. No significant difference in sex was observed between groups ($p = 0.533$).

175 We found no significant difference in age of onset ($p = 0.508$). With regard to diagnostic
176 group (schizophrenia spectrum disorders/affective psychotic disorders/other psychotic
177 disorders), we found no significant difference between groups ($p = 0.787$). No significant
178 difference in CGAS was observed between the groups ($p = 0.287$).

179 The five samples which were positive for NMDAR-Abs, had scores ranging from 1.5 (weak
180 positive) to 2.0 (moderate positive). Clinical characteristic of the five participants are
181 described in Table 2.

182 Two of the three patients who tested positive for antibodies displayed typical psychiatric
183 symptomatology and disease course with no neurological or radiological abnormalities. In
184 these two patients, we found no evidence of the broad range of symptoms seen in ANRE, nor
185 did we find any positive neurological signs or brain MR imaging findings such as white
186 matter hyper intensities on T2-weighted FLAIR coinciding with ANRE. One of the NMDAR
187 antibody positive HC had neither psychopathology, nor any neurological or MRI findings. We

188 observed one patient and one control with NMDAR-Abs and ANRE related symptomatology
189 or MRI findings.

190 *NMDAR-Abs Positive Adolescents with MRI Findings*

191 The first participant of interest was a 12 year-old female who was diagnosed with psychotic
192 disorder NOS. She had a prior diagnosis of obsessive-compulsive disorder (OCD) and body
193 dysmorphic disorder (BDD), as well as juvenile rheumatoid arthritis (JRA), the latter being
194 diagnosed months prior to the development of psychotic symptoms. Prior to illness onset, the
195 participant exhibited good premorbid school and social functioning.

196 At the time of inclusion, she presented with paranoid delusions, affective lability, aggression
197 and suicidal ideation as well as symptoms relating to OCD and BDD. Of note, there were no
198 hallucinations, no apparent negative symptoms and no cognitive deficits noted on her
199 neurocognitive examination. The neurological exam was without findings. MRI showed
200 minor lesions of vasculopathological origin located bi-frontally and in the right basal ganglia
201 (Figure 1). She was stabilized on aripiprazole with good effect on all of the symptoms she
202 presented with at the time of inclusion. After two years, the antipsychotic medication was
203 discontinued, and she has since been asymptomatic with regards to the psychotic disorder. A
204 few months prior to starting antipsychotic medication, the patient began a successful
205 treatment for JRA in the form of a tumor necrosis factor-alpha inhibitor.

206 The second participant who tested positive for NMDAR-Abs was a 17 year-old female in the
207 HC group. She had no prior or present psychopathology. The results from the neurocognitive
208 assessment were within normal range on all tests, and she had no neurological findings upon
209 inclusion. She had no prior somatic diseases or hospital admissions. She presented with a
210 single finding on a FLAIR MR pulse sequence consisting of a 5 mm white matter hyper
211 intensity lesion located in the left frontal lobe (Figure 2). This finding prompted a follow-up

212 MRI, which was conducted one month later without observed abnormalities, i.e. the prior
213 FLAIR abnormality was resolved. The same neuro-radiologist reviewed both scans. Neither at
214 time of inclusion, nor at MRI follow-up scan, did she present with any symptoms or
215 neurological findings coinciding with ANRE. Her school and social functioning remained
216 unremarkable. Further clinical follow-up was not indicated.

217

218 Discussion

219 From the multi-center Scandinavian cohorts, we report three adolescents in the EOP patient
220 group (6.5%) and two in the HC group (2.9%) who tested positive for NMDAR-Abs.
221 Antibody-positivity was seen in both sexes, across psychiatric diagnostic groups, and did not
222 affect function (measured by CGAS) compared to antibody negative EOP patients. Patients
223 with antibodies were younger than patients without antibodies. Further assessment of
224 antibody positive participants revealed a spectrum of clinical symptoms in the five
225 participants and specific MR findings in two participants. An unusual psychiatric presentation
226 was described in one of the participants.

227 Our finding of antibody-positive EOP patients is in line with Pathmanandavel and colleagues,
228 the only previous study reported in an adolescent EOP patients [17]. They identified serum
229 IgG NMDAR-Abs in five of the 43 EOP patients (11.6%). Patients in the Pathmanandavel et
230 al., study were well characterized clinically, but neuroimaging was only performed in 38 of
231 43 patients, of which 27 had MRI head scans (eleven patients had computed tomography head
232 scans). This is in contrast to our study, where all participants, both EOP patients and HC, had
233 MRI head scans. They did not find antibodies in any of their 43 control participants. These
234 were either healthy control subjects (n=17), patients with other neurological disease (epilepsy,
235 cerebral palsy, neurometabolic disease, and neurodegenerative disorders), general medical
236 control subjects (growth hormone deficiency, recurrent fractures, abdominal pain, infection),
237 or inflammatory neurological control subjects (including first episode of demyelination).

238 Their finding is in contrast to our results, as we identified HC with IgG antibodies. Though
239 small sample sizes may explain the difference in these findings, other differences such as the
240 use of carefully matched adolescent HC in our study, rather than partially pre-adolescent
241 children (their controls ranged from 4-18 years of age and thus were younger than those in our

242 study) and sensitivities and specificities of NMDAR-Abs assays used also could be an
243 explanation.

244 The prevalence of NMDAR-Abs in our study is also consistent with studies on adult
245 psychiatric patients, where a meta-analysis found that 21 of 1441 (1.46%) patients with
246 schizophrenia and other psychotic disorders were positive for IgG NMDAR-Abs [10]. The
247 same meta-analysis also identified that 5 of 1598 (0.3%) HC participants were IgG positive.
248 Another study has shown that ANRE can have an atypical disease course consisting mainly of
249 psychiatric symptoms [9]. In three antibody positive EOP patients identified in our study, two
250 had psychosis without obvious neurological symptoms or findings, and unremarkable MRI
251 scans. The third EOP patient with antibody-positivity was of particular interest due an unusual
252 presentation of disease onset. This patient presented with a wide range of psychiatric
253 symptoms, including comorbidity of OCD and BDD, abnormal findings bi-frontally and in
254 the basal ganglia on brain MRI and a recent diagnosis of a juvenile rheumatoid arthritis. It is
255 known that autoimmune diseases show a co-occurrence with other autoimmune diseases in as
256 many as 25% of patients [22] perhaps partly due to shared genetic variants [23]. The antibody
257 positive EOP patients in our study may represent a less severe disease course, rather than the
258 full neurological presentation of ANRE.

259 One of the two controls with NMDAR-Abs had an MRI finding in the form of a 5 mm white
260 matter hyperintensity lesion located in the left frontal lobe, which is the kind of hyperintensity
261 lesion common in ANRE patients [8], but which had disappeared on subsequent scanning.
262 White matter hyperintensity lesions are not uncommon in healthy populations, or in patients
263 with psychotic disorders [24], but are most commonly seen during aging [25]. The
264 significance of a fleeting MRI white matter intensity associated with a positive NMDAR-Abs

265 test could be indicative of a transient form of ANRE in a susceptible age group, but may also
266 be completely unrelated.

267 There are limitations. Several researchers in the field have pointed out difficulties in
268 identification of the antibodies [26] and in particular how low antibody titers may be present
269 in healthy individuals [10]. This is in line with the approach to autoimmune disorders in
270 general; where low titers may not represent the manifestation of an autoimmune disorder,
271 whilst higher titers are more likely to indicate the manifestation of a disease [27]. In addition,
272 false positives are not uncommon in other autoimmune disorders [28]. This appears also to be
273 the case with IgG NMDAR-Abs, as some studies have reported a seroprevalence of 1.2% and
274 0.4% in healthy populations [29, 30]. Moreover, we measured plasma antibodies rather than
275 those in cerebrospinal fluid (CSF). A previous study on ANRE patients by Gresa-Arribas and
276 colleagues showed a higher sensitivity for NMDAR-Abs in CSF rather than in serum (100%
277 vs. 85.6%) [31].

278 Scientific research has shown that EOP patients have a less favorable prognosis compared to
279 adult onset psychosis [15]. The number of studies conducted on EOP compared to adult
280 psychotic disorders is fewer because of the low prevalence of EOP in a population. Our
281 findings may represent a subgroup of patients with a range of symptoms associated with
282 antibody-positivity. Studying adolescent EOP patients, it might be easier to identify the
283 biological disease mechanisms as opposed to secondary phenomena associated with more
284 long-term psychosis disease phase found in adults.

285 ***Conclusions***

286 We report the detection of IgG NMDAR-Abs in plasma in 6.5% of EOP patients and 2.9% of
287 HC participants. Our findings may indicate that specific immune-mediated mechanisms
288 define a biological subgroup of psychosis patients. However, the five antibody positive

289 participants ranged from being symptom free to exhibiting symptoms and MRI findings
290 coinciding with ANRE. We conclude that testing of patients must be done in an individual
291 clinical context and that the presence of NMDAR-Abs must be carefully interpreted. Further
292 studies conducted on independent samples of EOP adolescents are needed in order to increase
293 understanding of the pathological significance of NMDAR-Abs in early psychosis.

294 **Acknowledgements**

295 The authors would like to thank all participants and their families for their contribution to this
296 study. We thank Dr. Vera Lonning for her important work in recruiting and assessing
297 Norwegian EOP patients and controls. We express our gratitude to the funding agencies: the
298 Research Council of Norway (#223273), the South-Eastern Norway Regional Health
299 Authority (#2014-114), the Swedish Research Council (K2012-61X-15078-09-3, K2015-
300 62X-15077-12-3 and 2017-00949) and FORMAS.

301

302

303 References

- 304 1. Carlsson A, Lindqvist M. Effect of Chlorpromazine or Haloperidol on Formation of 3-
305 Methoxytyramine and Normetanephrine in Mouse Brain. *Acta Pharmacologica et*
306 *Toxicologica*. 1963;20(2):140-4. doi: 10.1111/j.1600-0773.1963.tb01730.x.
- 307 2. Howes OD, Kapur S. The dopamine hypothesis of schizophrenia: version III--the final
308 common pathway. *Schizophrenia bulletin*. 2009;35(3):549-62. Epub 03/26. doi:
309 10.1093/schbul/sbp006. PubMed PMID: 19325164.
- 310 3. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, et al.
311 Subanesthetic Effects of the Noncompetitive NMDA Antagonist, Ketamine, in Humans:
312 Psychotomimetic, Perceptual, Cognitive, and Neuroendocrine Responses. *Archives of*
313 *General Psychiatry*. 1994;51(3):199-214. doi: 10.1001/archpsyc.1994.03950030035004.
- 314 4. Javitt DC. Glutamate and Schizophrenia: Phencyclidine, N-Methyl-d-Aspartate
315 Receptors, and Dopamine–Glutamate Interactions. In: Anissa AD, Olivier G, editors.
316 *International Review of Neurobiology*. Volume 78: Academic Press; 2007. p. 69-108.
- 317 5. Poels EMP, Kegeles LS, Kantrowitz JT, Slifstein M, Javitt DC, Lieberman JA, et al.
318 Imaging glutamate in schizophrenia: review of findings and implications for drug discovery.
319 *Molecular Psychiatry*. 2013;19:20. doi: 10.1038/mp.2013.136.
- 320 6. Moscato EH, Peng X, Jain A, Parsons TD, Dalmau J, Balice-Gordon RJ. Acute
321 Mechanisms Underlying Antibody Effects in Anti–N-Methyl-D-Aspartate Receptor
322 Encephalitis. *Annals of Neurology*. 2014;76(1):108-19. doi: 10.1002/ana.24195. PubMed
323 PMID: PMC4296347.
- 324 7. Dalmau J, Lancaster E, Martinez-Hernandez E, Rosenfeld MR, Balice-Gordon R.
325 Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis.
326 *The Lancet Neurology*. 2011;10(1):63-74. doi: 10.1016/S1474-4422(10)70253-2. PubMed
327 PMID: 21163445.
- 328 8. Dalmau J, Gleichman AJ, Hughes EG, Rossi JE, Peng X, Lai M, et al. Anti-NMDA-
329 receptor encephalitis: case series and analysis of the effects of antibodies. *Lancet neurology*.
330 2008;7(12):1091-8. doi: 10.1016/S1474-4422(08)70224-2. PubMed PMID: PMC2607118.
- 331 9. Kayser MS, Titulaer MJ, Gresa-Arribas N, Dalmau J. Frequency and characteristics of
332 isolated psychiatric episodes in anti–N-methyl-d-aspartate receptor encephalitis. *JAMA*
333 *neurology*. 2013;70(9):1133-9. doi: 10.1001/jamaneurol.2013.3216. PubMed PMID:
334 23877059.
- 335 10. Pollak TA, McCormack R, Peakman M, Nicholson TR, David AS. Prevalence of anti-
336 N-methyl-d-aspartate (NMDA) receptor antibodies in patients with schizophrenia and related
337 psychoses: a systematic review and meta-analysis. *Psychological Medicine*.
338 2013;44(12):2475-87. Epub 12/13. doi: 10.1017/S003329171300295X.
- 339 11. Werry JS, McClellan JM, Chard L. Childhood and Adolescent Schizophrenic, Bipolar,
340 and Schizoaffective Disorders: A Clinical and Outcome Study. *Journal of the American*
341 *Academy of Child & Adolescent Psychiatry*. 1991;30(3):457-65. doi: 10.1097/00004583-
342 199105000-00017.
- 343 12. Gillberg C, Wahlström J, Forsman A, Hellgren L, Gillberg IC. TEENAGE
344 PSYCHOSES—EPIDEMIOLOGY, CLASSIFICATION AND REDUCED OPTIMALITY
345 IN THE PRE-, PERI-AND NEONATAL PERIODS. *Journal of Child Psychology and*
346 *Psychiatry*. 1986;27(1):87-98. doi: 10.1111/j.1469-7610.1986.tb00624.x.
- 347 13. Boeing L, Murray V, Pelosi A, McCabe R, Blackwood D, Wrate R. Adolescent-onset
348 psychosis: prevalence, needs and service provision. *British Journal of Psychiatry*.
349 2018;190(1):18-26. Epub 01/02. doi: 10.1192/bjp.190.1.18.

- 350 14. Gore FM, Bloem PJN, Patton GC, Ferguson J, Joseph V, Coffey C, et al. Global
351 burden of disease in young people aged 10–24 years: a systematic analysis. The
352 Lancet. 2011;377(9783):2093-102. doi: 10.1016/S0140-6736(11)60512-6.
- 353 15. Kumra S, Charles Schulz S. Editorial: research progress in early-onset schizophrenia.
354 Schizophrenia bulletin. 2008;34(1):15-7. Epub 11/28. doi: 10.1093/schbul/sbm123. PubMed
355 PMID: 18048380.
- 356 16. Stentebjerg-Olesen M, Pagsberg AK, Fink-Jensen A, Correll CU, Jeppesen P. Clinical
357 Characteristics and Predictors of Outcome of Schizophrenia-Spectrum Psychosis in Children
358 and Adolescents: A Systematic Review. Journal of Child and Adolescent
359 Psychopharmacology. 2016;26(5):410-27. doi: 10.1089/cap.2015.0097.
- 360 17. Pathmanandavel K, Starling J, Merheb V, Ramanathan S, Sinmaz N, Dale RC, et al.
361 Antibodies to Surface Dopamine-2 Receptor and N-Methyl-D-Aspartate Receptor
362 in the First Episode of Acute Psychosis in Children. Biological Psychiatry. 2015;77(6):537-
363 47. doi: 10.1016/j.biopsych.2014.07.014.
- 364 18. World Health Organization. The ICD-10 classification of mental and behavioural
365 disorders: Clinical descriptions and diagnostic guidelines. Geneva: World Health
366 Organization; 1992.
- 367 19. Kaufman J, Birmaher B, Brent D, Rao UMA, Flynn C, Moreci P, et al. Schedule for
368 Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime
369 Version (K-SADS-PL): Initial Reliability and Validity Data. Journal of the American
370 Academy of Child & Adolescent Psychiatry. 1997;36(7):980-8. doi:
371 <https://doi.org/10.1097/00004583-199707000-00021>.
- 372 20. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS)
373 for Schizophrenia. Schizophrenia Bulletin. 1987;13(2):261-76. doi: 10.1093/schbul/13.2.261.
- 374 21. Shaffer D, Gould MS, Brasic J, Ambrosini P, Fisher P, Bird H, et al. A Children's
375 Global Assessment Scale (CGAS). Archives of General Psychiatry. 1983;40(11):1228-31.
376 doi: 10.1001/archpsyc.1983.01790100074010.
- 377 22. Mohan M, Ramesh T. Multiple autoimmune syndrome. Indian Journal of
378 Dermatology, Venereology, and Leprology. 2003;69(4):298-9.
- 379 23. Anaya J-M, Gómez L, Castiblanco J. Is there a common genetic basis for autoimmune
380 diseases? Clinical & developmental immunology. 2006;13(2-4):185-95. doi:
381 10.1080/17402520600876762. PubMed PMID: 17162361.
- 382 24. Sommer IE, de Kort GAP, Meijering AL, Dazzan P, Hulshoff Pol HE, Kahn RS, et al.
383 How frequent are radiological abnormalities in patients with psychosis? A review of 1379
384 MRI scans. Schizophrenia bulletin. 2013;39(4):815-9. Epub 03/13. doi:
385 10.1093/schbul/sbs037. PubMed PMID: 22416264.
- 386 25. Mineura K, Sasajima H, Kikuchi K, Kowada M, Tomura N, Monma K, et al. White
387 matter hyperintensity in neurologically asymptomatic subjects. Acta Neurologica
388 Scandinavica. 1995;92(2):151-6. doi: 10.1111/j.1600-0404.1995.tb01030.x.
- 389 26. Gastaldi M, Thouin A, Franciotta D, Vincent A. Pitfalls in the detection of N-methyl-
390 d-aspartate-receptor (NMDA-R) antibodies. Clinical Biochemistry. 2017;50(6):354-5. doi:
391 <https://doi.org/10.1016/j.clinbiochem.2016.11.023>.
- 392 27. Wang K-Y, Yang Y-H, Chuang Y-H, Chan P-J, Yu H-H, Lee J-H, et al. The initial
393 manifestations and final diagnosis of patients with high and low titers of antinuclear
394 antibodies after 6 months of follow-up. Journal of Microbiology, Immunology and Infection.
395 2011;44(3):222-8. doi: <https://doi.org/10.1016/j.jmii.2011.01.019>.
- 396 28. Slater CA, Davis RB, Shmerling RH. Antinuclear Antibody Testing: A Study of
397 Clinical Utility. Archives of Internal Medicine. 1996;156(13):1421-5. doi:
398 10.1001/archinte.1996.00440120079007.

- 399 29. Dahm L, Ott C, Steiner J, Stepniak B, Teegen B, Saschenbrecker S, et al.
400 Seroprevalence of autoantibodies against brain antigens in health and disease. *Annals of*
401 *Neurology*. 2014;76(1):82-94. doi: 10.1002/ana.24189.
402 30. Hammer C, Stepniak B, Schneider A, Papiol S, Tantra M, Begemann M, et al.
403 Neuropsychiatric disease relevance of circulating anti-NMDA receptor autoantibodies
404 depends on blood-brain barrier integrity. *Mol Psychiatry*. 2014;19(10):1143-9. doi:
405 10.1038/mp.2013.110.
406 31. Gresa-Arribas N, Titulaer MJ, Torrents A, Aguilar E, McCracken L, Leypoldt F, et al.
407 Antibody titres at diagnosis and during follow-up of anti-NMDA receptor encephalitis: a
408 retrospective study. *The Lancet Neurology*. 2014;13(2):167-77. Epub 12/18. doi:
409 10.1016/S1474-4422(13)70282-5. PubMed PMID: 24360484.

410

411

412

413

414

415
416

Table 1. Results of statistical analysis

	NMDA antibody positive patients (n=3)	NMDA antibody negative patients (n=43)	P-value	Statistical method
Age, years (SD)	14.46 ± 2.31	16.49 ± 1.17	0.026	Fisher-Pitman permutation test
Sex (F/M)	2/3	31/43	0.533	Fisher's direct exact test
Diagnostic group (SZ/AFP/OTP)	1/0/2	16/10/17	0.787	Fisher's direct exact test
Age of onset, years (SD)	13.81 ± 2.19	14.49 ± 2.17	0.508	Fisher-Pitman permutation test
CGAS (SD)	49.67 ± 12.86	41.35 ± 12.15	0.287	Fischer-Pitman permutation test

417 Abbreviations: SZ = schizophrenia spectrum disorders, AFP = affective psychotic disorders, OTP = other
418 psychotic disorders. CGAS = children's global assessment scale

419
420
421

Table 2. Clinical features and MRI findings in NMDAR-Abs positive participants

Age and sex	Family psychiatric history	Presenting psychiatric symptoms	Somatic co-morbidity	Neurological symptoms	Head MRI	Psychiatric diagnosis	Treatment and outcome
12, F	None	Affective lability. Aggression. Paranoid delusions. Suicidal ideation.	Juvenile rheumatoid arthritis	None	Multiple lesions of vasculopathological origin located bifrontally and in the right basal ganglia.	Psychotic disorder not otherwise specified 298.9	Previously used aripiprazole for one year. Presently unmedicated. Several rounds of inpatient and outpatient treatment.
16, M	Depression, father	Depressive symptoms. Depersonalization and derealization. Auditory, visual and tactile hallucinations.	None	None	Normal	Schizoaffective disorder, depressive type 295.7	Previously tried sertraline and mirtazapine. Unmedicated during study. One previous inpatient admission. Ongoing outpatient treatment.
14, F	Anxiety, maternal uncle	Anxiety. Depressive symptoms. Auditory hallucinations. Self harm.	None	None	Normal	Psychotic disorder not otherwise specified 298.9	Previously used risperidone, aripiprazole and melatonin. Patient stopped taking medication with no increase in symptoms following this. Ongoing outpatient treatment.
14, M	None	None	None	None	Normal	None	None
17, F	None	None	None	None	5 mm FLAIR hyper intensity lesion located in the left frontal lobe. Follow-up MRI taken 1 month later was normal (i.e. no lesion)	None	None

Figure 1: T1-weighted images showing several lesions of vasculopathological origin located bi-frontally and in the right basal ganglia, shown here in axial (a), sagittal (b) and coronal (c) view.

Figure 2: T2 weighted FLAIR image showing a 5 mm hyper intensity lesion in the left frontal lobe.



